Beyond B cells

PureTech Health plc subsidiary Vor Biopharma Inc. plans to combine CAR T therapies with hematopoietic stem cells modified to go unrecognized by CAR Ts. The approach could increase the types of immune cells that can be targeted by this modality for hematologic malignancies and eliminate the on-target toxicities of existing CAR T agents.

PureTech VP Aleks Radovic-Moreno, who is Vor program lead, said tumor-specific targets for CAR T therapies have been difficult to identify, as “antigens are almost always co-expressed on normal cells, or they are very rare, patient-specific and not suitable targets.”...